SCHEMBL4818147

SCHEMBL4818147

CC(C)(C)ON(C=O)CCCCO

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.33
CYP4F2 P78329 1/20 0.30
CYP4A11 Q02928 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6676603 0.98 TDP1 (0.36) TDP1CYP4F2CYP4A11
SCHEMBL29000774 0.98 TDP1 (0.36) TDP1CYP4F2CYP4A11
SCHEMBL1467658 0.94 TDP1 (0.31) TDP1
SCHEMBL5156789 0.86
SCHEMBL7704514 0.81 CHRM2 (0.35)
SCHEMBL6209232 0.80 ADH1C (0.36)
SCHEMBL7386766 0.79 ADH1C (0.30)
SCHEMBL7391165 0.79 ADH1C (0.30)
SCHEMBL989108 0.79 CHRM2 (0.39)
SCHEMBL9866159 0.79 TSHR (0.40) TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115353770-B Gel pen ink with optimized writing performance 南京一墨纳米技术有限公司 2023-10-20 CN claimed
CN-115353770-A Gel pen ink with optimized writing performance 南京一墨纳米技术有限公司 2022-11-18 CN claimed
CN-114437585-A Writing pen ink for files and preparation method thereof 鼎纳科技有限公司 2022-05-06 CN claimed
CN-118206559-A PROTAC chimeric compounds, preparation method and use thereof 杭州中美华东制药有限公司 2024-06-18 CN disclosed
CN-117777187-A Triphenyl phosphate hapten as well as preparation method and application thereof 北京维德维康生物技术有限公司 2024-03-29 CN disclosed
CN-117305301-A Oligonucleotide for inhibiting ASGPR-1 gene or pharmaceutically acceptable salt thereof and application 弘亮(上海)生物医药科技有限公司 2023-12-29 CN disclosed
CN-116120390-B Tripterine derivative and preparation method and application thereof 中国药科大学 2023-12-22 CN disclosed
CN-117003744-A Five-membered and six-membered compound, intermediate, preparation method, composition and application 厦门市博瑞来医药科技有限公司 2023-11-07 CN disclosed
CN-116903684-A Liver targeting compound and oligonucleotide conjugate and application thereof 弘亮(上海)生物医药科技有限公司 2023-10-20 CN disclosed
CN-116732034-A Oligonucleotide for inhibiting AGT gene or pharmaceutically acceptable salt thereof and application 弘亮(上海)生物医药科技有限公司 2023-09-12 CN disclosed
CN-116406272-A DNA-PK selective inhibitor and preparation method and application thereof 首药控股(北京)股份有限公司 2023-07-07 CN disclosed
CN-116120390-A Tripterine derivative and preparation method and application thereof 中国药科大学 2023-05-16 CN disclosed
CN-115353770-A Gel pen ink with optimized writing performance 南京一墨纳米技术有限公司 2022-11-18 CN disclosed
US-7365174-B2 Azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2008-04-29 US disclosed
US-20070042974-A1 Nozel azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2007-02-22 US disclosed
EP-1661904-A1 NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2006-05-31 EP disclosed
EP-0779281-B1 ISOXAZOLES SANKYO CO (JP) 2003-10-29 EP disclosed
US-6096771-A ISOXAZOLE DERIVATIVES EXHIBITING EXCELLENT TYPE B AND TYPE A MONOAMINE OXIDASE INHIBITORY ACTIVITIES, THEREFORE USEFUL FOR PREVENTING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE SANKYO COMPANY, LIMITED (JP) 2000-08-01 US disclosed
US-5965591-A MONOAMINE OXIDASE INHIBITOR; FOR PROPHYLAXIS AND TREATING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE SANKYO COMPANY, LIMITED (JP) 1999-10-12 US disclosed
EP-0779281-A1 ISOXAZOLES SANKYO COMPANY LIMITED (JP) 1997-06-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070042974-A1 Nozel azalide and azalactam derivatives and method for producing the same BCL6, NR4A1, NR4A2 TDP1 4481/4885CYP4F2 796/4885CYP4A11 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.